Search Results - "Ardèvol, Mercè"
-
1
-
2
Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients
Published in PloS one (28-08-2013)“…Only about 50% of patients chronically infected with HCV genotype 1 (HCV-1) respond to treatment with pegylated interferon-alfa and ribavirin (dual therapy),…”
Get full text
Journal Article -
3
Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors
Published in PloS one (30-11-2010)“…Current treatment of chronic hepatitis C virus (HCV) infection has limited efficacy -especially among genotype 1 infected patients-, is costly, and involves…”
Get full text
Journal Article -
4
Potential drug–drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice
Published in Journal of gastroenterology and hepatology (01-05-2018)“…Background & Aims Drug–drug interactions (DDIs) with ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin…”
Get full text
Journal Article -
5
Prophylactic Treatment With Escitalopram of Pegylated Interferon Alfa-2a―Induced Depression in Hepatitis C: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Published in The journal of clinical psychiatry (01-04-2011)“…Depression is one of the main reasons for treatment withdrawal and failure in chronic hepatitis C patients treated with interferon. Antidepressants are useful…”
Get full text
Journal Article -
6
Role of ribavirin in interferon-free therapy for the treatment of hepatitis C virus
Published in Gastroenterología y Hepatología (English Edition) (01-12-2017)Get full text
Journal Article -
7
Relevance of Baseline Viral Genetic Heterogeneity and Host Factors for Treatment Outcome Prediction in Hepatitis C Virus 1b-Infected Patients: e72600
Published in PloS one (01-08-2013)“…Background Only about 50% of patients chronically infected with HCV genotype 1 (HCV-1) respond to treatment with pegylated interferon-alfa and ribavirin (dual…”
Get full text
Journal Article